Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 143% above its 3-year average of 0.00, near the low end of its 3-year range (0.00–0.13).
As of the fiscal period ended Tuesday, June 30, 2026. 16.28% above its 12-month average of 0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.01
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+16.28%
CURRENT VS 3Y AVG
+125.43%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 716 covered companies
CURRENT VS SECTOR MEDIAN
-92.21%
vs the sector median at left
Market Cap
$5.75B
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$5.52B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$5.82B
Debt to Equity Ratio
1.57
TTM Avg
0.74
3Y Avg
0.65
5Y Avg
0.49
Market Cap
$5.92B
Debt to Equity Ratio
0.06
TTM Avg
0.08
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$5.94B
Debt to Equity Ratio
1.17
TTM Avg
0.23
3Y Avg
0.15
5Y Avg
0.27
Market Cap
$5.29B
Debt to Equity Ratio
N/A
TTM Avg
441.80
3Y Avg
221.15
5Y Avg
147.72
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.62B | 0.01 | 0.01 | 0.00 | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.75B | 0.01 | 0.02 | 0.02 | 0.02 |
| RadNet, Inc. (RDNT)vs › | $5.53B | 1.99 | 1.81 | 2.63 | 3.97 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 0.02 | 0.02 | 0.01 | 0.01 |
| Kodiak Sciences Inc. (KOD)vs › | $5.82B | 1.57 | 0.74 | 0.65 | 0.49 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | 0.06 | 0.08 | 0.11 | 0.11 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 1.17 | 0.23 | 0.15 | 0.27 |
| Doximity, Inc. (DOCS)vs › | $5.30B | 0.01 | 0.01 | 0.02 | 0.01 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.29B | N/A | 441.80 | 221.15 | 147.72 |
| GRAIL Inc. (GRAL)vs › | $6.02B | 0.04 | 0.04 | 0.03 | 0.04 |
Debt/Equity
0.01
Current Ratio
22.22
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.01 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.13 |
